In the STEP-1 trial of 1,961 adults (Wilding and colleagues, Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 2021), participants on semaglutide 2.4 mg lost an average of 14.9 percent of their body weight at 68 weeks, compared to 2.4 percent on placebo
Before you use the medication Read the information leaflets that come in the box
Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition or treatment
9 The original Diabetes Prevention Program (DPP) trial, published in 2002, showed that intensive lifestyle change (a 7% weight loss target plus 150 minutes of physical activity per week) reduced the incidence of type 2 diabetes by 58% over 3 years
GLP-1 provides the strong appetite suppression that makes eating less feasible and sustainable